	Application Number	10531884
	Filing Date	2006-04-11
INFORMATION DISCLOSURE	First Named Inventor   David	HAIGH
STATEMENT BY APPLICANT	Ari Unit	1626
( Not for submission under 37 CFR 1.99)	Examiner Name Chen	g, Karen
	Attorney Docket Number	PG4890USW

***************************************	**********		••••••		U.S.F	ATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>			thise of Applicant Palement P		s Columns Lines where ant Passages or Relev as Appear		
~	,	cannot read		1695-01-		Aigletal				
if you wis	n to as	dd additional U.S. Pate				***********				
	,	·	U.S.P	ATENT /	/PPLIC	CATION PUB	LICATIONS	······		
Exeminor Initial*	Citte No	Publication Number	Kind Code <sup>1</sup>	Publicat Date	Son	Name of Patentes or Applicant of cited Document		Relev	s,Columns,Lines when ant Passages or Releves as Appear	
	1								·	
If you wis	h io a	i. Id additional U.S. Publ	ished As	i. Oplication	citatio	r information ;	olease click the Ad	d bulto	ß.	
***************************************	•••••			FOREIG	N PAT	ENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>a</sup>	Countr Code <sup>2</sup>		Kind Code*	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	75
/KC/	4	9929705	wo		A2	1999-08-17	Glycomed Incorporated			
/KC	2	99/37304	wo		Αŝ	1899-07-29	RHONE-POULENC RORER PHARMACEUTICALS INC			0
/KC/	3	2002/44188	wo		A2	2002-06-06	SCIOS INC.			
<u> </u>	. <b>3</b>	.i				ž			;	÷

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10531684		
Filing Date	2008-04-11		
First Named Inventor	David HAIGH		
Art Unit	1628		
Examiner Name	ig, Karen		
Attorney Docket Numb	r PG4890USw		

/KC/	4	98/33170	wo	Ai	1995-10-24	CIBA-GEIGY AG		
/KC/	5	2004037818	wo	Aİ	2004-05-06	Giaxo Group Limited		
/KC/	8	g3g378@5	wo		2003-05-08			
/KC/	7	23037895	wo	Āī	2003-05-08	Glaxo Group Limited		
if you wis	h to a	t dd additional Foreigi	<u> </u>		*******************************	itease click the Add butto	ţ	
			NON-P	ATENT LII	ERATURE DO	CUMENIS	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	·····
Examiner initials*	Cite No	Include name of the author (in CAP)TAL LETTERS), title of the article (when appropriate), title of the item (book, mägazine, journal, serial, symposium, catalog, atc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						TE
/KC/	1	SATO ET AL; Heteropycles: 1994: 37/1: 245-248;						
/KC/	2	P. DE CAPRARIIS, G DE MARTINO, E. ABIGNENTE, P AVARA. L MAYO: Pýrrolo[1.4]benzodiazepines. IV Synthesis of E- and Z-5.11-Dioxo-11a-ethoxycarbonyl-2-ethylidine-1,2,3,10,11,11a-hexahydro-5Hpyrolo[2,1-0][1,4] benzodiazepine: J. Heterocyclic Chem.: Jan 89; 26; 1023-1027;						
/KC/	3	GARDINER, JAMES ET AL; Synthesis and solid state conformation of phenylalanina mimatics constrained in a proline-like conformation; Organic & Biomolecular Chemistry; 27 July 2004; 2(18): 2385-2370;						
/KC/	*	IKEDA M., ET AL.: Synthesis of trioyolic nitrogen-containing heterocycles by palladium-calalyzed cyclization of 2- alkenyl-n-(o-lodobenzoyl)- and 2-alkenyl-p-(o-lodophenylacatyl)-pyrrolidines; Heterocycles; 1998; 42; pgs. 155-158;						
/KC/	ö	CONFALONE P.N., ET AL.; Design and synthesis of potential DNA cross-linking reagents based on the anthramyoln class of minor groove binding compounds; J. Org. Chem.; 1988; 53; pgs. 482-487;						

/Karen Cheng/

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10531884
Filing Date	2008-04-11
First Named Inventor David	нован
Art Unit	1826
Examiner Name Chen	g, Karen
Attorney Docket Number	PG4880USW

			gamman,					
/KC/	ŝ	ALIG L., ET AL.; Low molecular weight, non-peptide fibrinogen receptor antagonista: J. Med. Chem.; 1992; 35; pgs. 4393-4407;						
/KC/	7	PADWA A., ET AL.; Transmutations of 1,3-dipoles. The conversion of a-diazo ketones into azomethine yildes visi carbonyl yildes; J. Am. Chem. Soc.; 1992; 114; pgs. 593-601;						
/KC/	8.	CULBERTSON T.P., ET AL.; Quincione ambacterial agents substituted at the 7-position with splinamines. Synthesis and structure-activity relationships; J. Med. Chem.; 1890; 33; pgs. 2270-2275;						
/KC/	0	CROOKS, P.A., ET AL.; Synthesis of 5-hydrexy- and 5,5-dihydroxy-derivatives of spirofindane-2,2'-pyrrolidine], rigid analogues of tyremine and departine respectively, Journal of the Chemical Society, Perkins Transactions 1; 1979; 11; pgs. 2719-2728;						
/KC/	10	DE MARTINO G., ET AL.; La Reazione Tra 2-Nitrobenzoliaminomalonato Ed Aldeide Acrilica Per LA Síntesi D Compositi A Struttura Pirrotoj2,1-c] [1,4]Benzodiazepinica (english summary only); Fermaco Ed Sc.; 1976; 31(11); pgs. 788-790;						
/KC/	11	IKEDA ET AL: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry: 1997/ 22; 3339-3344;						
/KC/ 12 SATO ET Al.; Journal of the Chemical Society, Perkin Transactions 1; 1995; 14; 1801-1809;								
if you wis	if you wish to add additional non-patent literature document citation information please click the Add button							
EXAMINER SIGNATURE								
Examiner Signature /Karen Cheng/ Date Considered 07/17/2007								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
Standard 3 4 Kind of de	Y.S). * Kanada	of USPTO Patent Documents at was LISPTO GOV or MPEP 901.04. * Enter office that issued the document, by the two-letter code (V) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document upder VVPO Standard ST.16 if possible. * Applicant is to place a check mark renalisticn is attached.	uesent.					